贝舒地尔不同版本一盒的最新价格公布

Introduction: Besudil is a kinase inhibitor mainly used to treat patients with chronic graft-versus-host disease (chronic GVHD) in adults and children aged 12 years and above who have failed at least two previous lines of systemic therapy. This article will introduce in detail the latest price of a box of different versions of Besudil, its domestic availability and medical insurance reimbursement status.

The latest prices for a box of different versions of Besudil are announced

The winning bid price included in medical insurance is approximately US$5,633, and the price after reimbursement will be lower.

The specification of besudil mesylate produced by Sanofi in France is 200mg*30 tablets per box, and the price is approximately US$6,510 per box. In addition, Lucius’s generic version of Besudil is 200mg*30 pills per box, and the price is approximately US$558 per box.

There are differences in the prices of different versions of Besudil. Patients are advised to refer to the actual price. The above prices are for reference only.

Besudil’s domestic marketing status

Besudil was first approved for marketing in the United States in 2021, and subsequently completed the relevant approval processes in China and officially entered the Chinese market. As the first domestic kinase inhibitor for the treatment of chronic GVHD, the launch of besudil provides patients with new treatment options, helping to improve disease prognosis and quality of life.

Marketing background and significance

Chronic GVHD is one of the common complications after hematopoietic stem cell transplantation, which seriously affects the patient's quality of life and prognosis. The launch of Besudil has filled the gap in this treatment field in China and provided patients with more precise and effective treatment options. At the same time, the launch of this drug also promotes the innovative development of the domestic pharmaceutical industry and enhances my country's competitiveness in the international pharmaceutical market.

Market response and prospects

Since Besudil was launched in China, it has attracted widespread attention from patients and medical institutions. Its unique mechanism of action and significant clinical efficacy bring new hope to patients. With the continuous improvement of market awareness and the gradual promotion of clinical applications, Besudil is expected to achieve even better performance in the domestic market.

The medical insurance reimbursement situation of Besudil

As for the medical insurance reimbursement situation of Besudil, there are currently differences in different regions and policies. Besudil has been included in the reimbursement scope of the medical insurance catalog in some areas, but the specific reimbursement ratio and conditions need to be implemented according to local medical insurance policies. Therefore, patients should consult the local medical insurance department or medical institution to understand the specific reimbursement policies and procedures before purchasing drugs.

The importance of medical insurance reimbursement

Medical insurance reimbursement is of great significance in reducing patients' financial burden and improving drug accessibility. The inclusion of Besudil in the medical insurance catalog can reduce patients' out-of-pocket expenses and allow more patients to benefit from this innovative drug.

Reimbursement Application Guide

For patients who meet the conditions for medical insurance reimbursement, they can submit a reimbursement application to the local medical insurance department or medical institution after purchasing the drug. When applying, you need to provide relevant drug purchase invoices, medical records, medical insurance reimbursement application forms and other materials. The specific application process and required materials can be queried and prepared according to local medical insurance policies.